Skip to main content
SpringerLink
Log in

Spotlight on Eltrombopag in Treatment-Refractory Chronic Primary Immune Thrombocytopenia

  • Adis Spotlight
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Eltrombopag (Revolade®) is an orally bioavailable, low molecular weight, synthetic nonpeptide thrombopoietin receptor agonist, which selectively binds to the transmembrane and juxtamembrane domains of the thrombopoietin receptor on the surface of platelets, megakaryocytes, and megakaryocyte precursor cells, resulting in responses similar to those induced by recombinant human thrombopoietin. Eltrombopag does not compete with thrombopoietin for its binding domain on the thrombopoietin receptor, and is highly selective. This article provides an overview of the pharmacological properties of eltrombopag and reviews the clinical efficacy and tolerability of the drug in adult patients with chronic primary immune thrombocytopenia (ITP).

In well designed 6-week and 6-month trials, eltrombopag was more effective than placebo at increasing platelet count and decreasing the incidence of bleeding in patients with treatment-refractory chronic ITP, and was generally well tolerated in these patients. Long-term (median duration 100 weeks) data from a noncomparative trial support these results. Importantly, previous splenectomy did not appear to have an effect on the efficacy of eltrombopag. As the first licensed oral thrombopoietin receptor agonist, eltrombopag may be a more convenient option than other ITP medications; however, it may be a costly option long term, as platelet counts generally return to baseline levels following treatment cessation, implying that continued treatment may be advised. Long-term treatment is often necessary in patients with chronic ITP, as curative rates with any treatment are very low.

Eltrombopag was generally well tolerated in clinical trials in patients with chronic ITP. Hepatobiliary abnormalities occurred in a greater proportion of eltrombopag than placebo recipients; however, these were usually mild and reversible. Other potential concerns, such as thromboembolic events, cataracts, and increased bone marrow reticulin, need to be further investigated.

Eltrombopag is an effective treatment option for adult patients with chronic ITP and an increased risk of bleeding who are refractory to previous treatments, including splenectomy, as demonstrated in well designed clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietin receptor agonist. Stem Cells 2009; 27: 424–30

    Article  PubMed  CAS  Google Scholar 

  2. Erickson-Miller C, Kirchner J, Payne P, et al. Eltrombopag does not enhance proliferation of non-megakaryocytic leukemia and lymphoma cell lines [abstract no. P067]. Leuk Res 2009; 33Suppl. 1: S98

    Article  Google Scholar 

  3. Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro [abstract no. 3888]. Blood 2004; 104 (11)

  4. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007 Jun 1; 109 (11): 4739–41

    Article  PubMed  CAS  Google Scholar 

  5. Psaila B, Bussel JB, Linden MD, et al. In vivo effects of eltrombopag on human platelet function [abstract no. 1301]. Blood 2007 Nov 1; 110 (11): 391–2

    Google Scholar 

  6. Mitchell W. The effect of eltrombopag on human platelet resistance to apoptosis: the role of the Bcl-XI pathway [abstract no. 2520]. Blood 2010; 116 (21)

  7. Gibiansky E, Zhang J, Williams D, et al. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol 2011; 51 (6): 842–56

    Article  PubMed  CAS  Google Scholar 

  8. European Medicines Agency. Revolade® (eltrombopag tablets): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001110/WC500089964.pdf [Accessed 2011 Jun 9]

  9. European Medicines Agency. CHMP assessment report for Revolade (eltrombopag tablets). Procedure no. EMEA/H/C/001110. Doc. ref. EMA/CHMP/ 279276/2010 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001110/WC500089967.pdf [Accessed 2011 Jun 9]

  10. Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther 2009 Apr; 31 (4): 764–76

    Article  PubMed  CAS  Google Scholar 

  11. Bauman JW, Vincent CT, Peng B, et al. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics. J Clin Pharmacol 2011; 51 (5): 739–50

    Article  PubMed  CAS  Google Scholar 

  12. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009 Feb 21; 373 (9664): 641–8

    Article  PubMed  CAS  Google Scholar 

  13. Bussel J, Psaila B, Saleh M, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura [abstract no. 3431]. Blood 2008; 112 (11): 1176

    Google Scholar 

  14. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study [published errata appear in Lancet 2011: 377 (9763): 382 and Lancet 2011; 377 (9766): 640]. Lancet 2011 Jan 29; 377 (9763): 393–402

    Article  PubMed  CAS  Google Scholar 

  15. Saleh MN, Cheng G, Bussel JB, et al. EXTEND study update: safety and efficacy of eltrombopag on adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2010 [abstract no. 67]. Blood 2010; 116 (21). Plus oral presentation at the 52nd Annual Meeting and Exposition of the American Society of Hematology, 2010 Dec 4–7; Orlando (FL)

  16. Bussel J, Saleh M, Salama A, et al. Improvement in fatigue and health-related quality of life with long-term eltrombopag treatment in adults with chronic idiopathic thrombocytopenic purpura: The EXTEND study [abstract no. 0239]. Haematologica 2009; 94Suppl. 2: 94–5

    Google Scholar 

  17. Bussel JB, Cheng GO, Saleh MN, et al. Incidence of thromboembolic events across eltrombopag clinical trials in chronic immune thrombocytopenia (ITP) [abstract no. 70]. Blood 2010; 116 (21). Plus oral presentation at the 52nd Annual Meeting and Exposition of the American Society of Hematology; 2010 Dec 4–7; Orlando (FL)

  18. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007 Nov 29; 357 (22): 2237–47

    Article  PubMed  CAS  Google Scholar 

  19. Bussel J, Saleh M, Meyer O, et al. Results of bone marrow examinations in patients with chronic idiopathic (immune) thrombocytopenic purpura treated with eltrombopag for more than one year [abstract no. 0604]. Haematologica 2010; 95 (s2): 253–254. Plus oral presentation at the 15th Congress of the European Hematology Association; 2010 Jun 10–13; Barcelona

    Google Scholar 

  20. Garnock-Jones KP. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia. Drugs 2011; 71 (10): 1333–53

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments and Disclosures

The full text article[20] from which this spotlight was derived was reviewed by: E. Andres, Service de Médecine Interne, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; M. Minkov, Department of Hematology/Oncology, St Anna Childrens Hospital, Vienna, Austria; S. Panzer, Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria; B. Tavil, Department of Childrens Hematology and Oncology, Ankara Training and Research Hospital, Ankara, Turkey; J.-W. van der Velden, Mesama Consulting, Schinznach Bad, Switzerland.

The manufacturer of the agent under review was offered an opportunity to comment on the original article[20] during the peer review process; changes based on any comments received were made by the author on the basis of scientific and editorial merit. The preparation of the original article and this spotlight was not supported by any external funding.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Karly P. Garnock-Jones

Authors
  1. Karly P. Garnock-Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karly P. Garnock-Jones.

Additional information

Adapted and reproduced from the original article published in Drugs 2011; 71 (10): 1333–1353

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garnock-Jones, K.P. Spotlight on Eltrombopag in Treatment-Refractory Chronic Primary Immune Thrombocytopenia. BioDrugs 25, 401–404 (2011). https://doi.org/10.2165/11207620-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11207620-000000000-00000

Keywords

Search

Navigation